targeted therapy for breast cancerWhen scientists became more aware of the genetic mutations in cells that cause cancer, they are engaged in the development of new drugs aimed at these changes. These targeted drugs work differently from standard chemotherapy. They are characterized by different and often less severe side effects.

Cost of targeted therapy of breast cancer in Israel from 1000 $.

Our organization, the medical service «Tlv.Hospital», offers the organization of targeted therapy in Israel - reasonable cost of treatment from the best doctors, perfect organization as soon as possible, domestic support, and additional services.

Consider the basic drugs targeted therapy used in Israel in the treatment of breast cancer .

Breast Cancer Targeted drug therapy aimed at the protein HER2 / neu

Approximately 1 in 5 patients with breast cancer on the surface of malignant cells too much protein - HER2 / neu (or just HER2), contributing to their growth. This type of cancer usually grows rapidly and spread more aggressively, if treatment is not carried out. It has developed a number of drugs targeted against HER2 / neu.

None of these drugs is not safe during pregnancy as they can cause damage or even lead to death of the fetus. In carrying out targeted therapy of breast cancer for women who have not reached menopause period, it is necessary to use effective contraception.

Targeted therapy of breast cancer: Trastuzumab (Herceptin)

Trastuzumab (Herceptin) - one of the drugs known as monoclonal antibodies, technogenic version specific protein of the immune system. It attaches to the HER2 protein and can help slow the growth of cancer cells with too much of the substance. Moreover, Herceptin also stimulates the immune system to deal more effectively with cancer.

Acceptance of the drug administered intravenously, usually once a week or more doses - once every 3 weeks.

Trastuzumab is often used as adjuvant therapy (after surgery) HER2-positive breast cancer to reduce the risk of the disease returning. First carried out a joint treatment with chemotherapy and then separately, a total for the year. Herceptin may also be administered prior to surgery as a neoadjuvant therapy.

Furthermore, Trastuzumab is used to treat a relapse of the disease, as well as in the case of growth of the tumor during therapy. The combination of chemotherapy and Herceptin works better than chemotherapy alone. If the cancer progresses, often continue treatment with trastuzumab and chemotherapy vary.targeted therapy for breast cancer

Compared with chemotherapy, Herceptin side effects manifested in relatively mild. These undesirable effects are rare and may include fever and chills, headache, weakness, cough, nausea, vomiting and diarrhea. they are usually mild.

More serious side effect is considered to damage the heart, which leads to a so-called congestive heart failure. For most (but not all) women, this symptom is temporary and disappears after discontinuation of the drug. The risk of those side effects increases, trastuzumab when combined with certain chemotherapeutic agents such as doxorubicin (Adriamycin) and epirubicin (Ellence). For this reason, the heart is checked regularly during treatment. The main symptoms of congestive heart failure are shortness of breath, swelling of the legs and severe fatigue. If you have any of these signs of the patient have to inform your doctor.

Targeted Breast Cancer Therapy: Ado-trastuzumab emtansine (TDM-1, Kadcyla ™)

Ado-trastuzumab emtansine is a drug-antibody conjugates categories of drugs, consisting of the same monoclonal antibody found in herceptin and chemotherapy, known as DM-1. In this type of drug antibody acts as a targeting device, delivering a chemotherapeutic agent directly to malignant cells.

Kadcyla used for the treatment of advanced breast cancer, in the form of injections every 3 weeks. Common side effects include fatigue, nausea, pain in the muscles and bones, low platelet count, headache and constipation. There may be more serious adverse events such as severe allergic reactions, liver damage and heart, lung problems.

Targeted therapy of breast cancer: Pertuzumab (Perjeta ®)

Like trastuzumab, pertuzumab is a monoclonal antibody that attaches to the HER2 protein. This drug may administered together with docetaxel (Taxotere) and trastuzumab for the treatment of advanced breast cancer, and the early stages of the disease as a neoadjuvant (before surgery).

Pertuzumab given intravenously every 3 weeks. Common side effects include diarrhea, hair loss, nausea, fatigue, rash and low white blood cell count (sometimes with fever).

Pertuzumab for heart disease do not apply, because it can weaken the body. Doctors in Israel are studying the condition of the heart, before you assign this drug every few months during therapy, they pertuzumab monitor and check the status of the heart muscle.

Targeted therapy of breast cancer: Lapatinib (Tykerb)

Targeted therapy of breast cancerLapatinib is another drug that targets the HER2 protein. The indication is a diagnosis - advanced HER2-positive breast cancer, the treatment of which proved to be ineffective chemotherapy and trastuzumab. Tykerb also be combined with Xeloda and letrozole (Femara). In pill form.

One study showed greater efficacy of lapatinib along with trastuzumab in metastatic breast cancer compared to one receiving lapatinib.

The most common side effects of this drug include diarrhea, nausea, vomiting, rash and hand-foot syndrome. Diarrhea is a common adverse event of treatment and can be very serious, so it is important to tell your doctor about any changes related to the functioning of the intestines.

In rare cases lapatinib can cause problems with liver or decline of heart function (which can lead to shortness of breath), but symptoms usually go once treatment is terminated.

Targeted therapy of breast cancer: Everolimus (Afinitor ®)

Everolimus is a type of targeted therapy that blocks the protein mTOR. This protein synthesis at the ribosome coordinates of many proteins, including those associated with reproduction and growth of cells. Excessive activation of mTOR function triggers uncontrolled cell division - ie their transformation into malignant. By blocking the protein, it is possible to prevent the growth of cancer cells. Everolimus is also able to stop the development of new blood vessels in the tumor, which would limit its growth. In the treatment of breast cancer increases the effectiveness of everolimus hormone therapy.

Everolimus - this pill that must be taken once a day.

This drug is approved for the treatment of advanced hormone-positive, HER2-negative breast cancer in post-menopausal women. It is prescribed with exemestane (Aromasin), when the tumor has grown at a time when the treatment was carried letrozole or anastrozole.Targeted therapy of breast cancer

Common side effects of this drug include mouth sores, diarrhea, nausea, fatigue, weakness, low blood counts, shortness of breath and cough. Everolimus may also increase the levels of blood lipids (cholesterol and triglycerides) and sugar. Therefore, while taking the drug, doctors do blood tests to monitor the state of the body. Everolimus is also able to increase the risk of serious infections.

Afinitor study for the application at an early stage of breast cancer with other drugs and hormonal therapy in combination with various methods of treatment.

Targeted therapy of breast cancer: bevacizumab (Avastin ®)

The tumor must create and develop new blood vessels to grow. Drugs that target these vessels to be effective against various types of cancer and have been studied in the treatment of breast cancer.

Bevacizumab is a monoclonal antibody which is administered to patients with the diagnosis of metastatic breast cancer. This antibody is directed against vascular endothelial growth factor (VEGF), a protein that helps tumors create new blood vessels.

Bevacizumab is administered intravenously, often enough - in combination with chemotherapy.

Rare but potentially serious side effects include bleeding, ulcers formed in the colon requiring surgery, slow healing of wounds.

By the more common side effects include high blood pressure, fatigue, clots, decreased number of white blood cells, headache, oral ulcers, loss of appetite and diarrhea. High blood pressure is very common, so it is important that the physician monitor this symptom during treatment.

Bevacizumab was first approved by the FDA in the US as part of a comprehensive treatment of metastatic breast cancer in 2008. This statement was based on a study wherein receiving bevacizumab chemotherapy with paclitaxel (Taxol) tumor growth stopped for a longer time than the use of one drug paclitaxel.

Targeted therapy of breast cancerNew study results presented in July 2010, the FDA, showed no treatment advantage of bevacizumab. Although the drug seemed to slow cancer growth in a short time, some of the women, it did not increase their life expectancy. Therefore, considering the much more serious side effects of bevacizumab, the FDA concluded that the risk outweighs the benefits of this drug in the treatment of metastatic breast cancer. November 18, 2011 FDA withdrew the drug from the testimony of the diagnosis of breast cancer. This does not mean that the drug will not be available because it is still approved for the treatment of certain other types of cancer. This means that the company that manufactures bevacizumab, can not sell it as a drug for treating this type of cancer, and can not recommend it to doctors or patients as a drug used in the treatment of this disease. At the same time, women who are taking bevacizumab can continue to receive, but they should discuss this treatment with your doctor.

Tlv.Hospital Coordination Center will assist in the diagnosis of the organization and treatment of breast cancer in Israel, including targeted therapies. Modern possibilities of Israeli medicine guarantee the best results in the treatment of oncology.

Personalized approach to targeted therapy allows you to accurately select products based on genetic tests that detect the presence of a particular mutation of tumor cells.

Online video consultations with leading Israeli experts: about the benefits of online video consultation.